Please assess the completion status of the following clinical trial:

Trial Title: Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult trauma patients admitted to ICU within 24 hours from trauma onset with injury severity score (ISS) ≥ 16 will be recruited after obtaining informed consent~Exclusion Criteria:~* • Patients admitted to ICU after time exceeding 24 hours from trauma onset.~  * Patients whose age is less than 18 years.~ * Pregnant female.~ * Breast feeding women.~ * Arrest within 24 hours of admission.~ * Immune deficiency or administration of immune suppressant drugs.~ * Serum calcium greater than or equal to 10 mg/dl or phosphate greater than or equal 6 mg/dl.~ * History of primary parathyroid disease.~ * Metabolic bone disease.~ * Sarcoidosis.~ * End stage renal disease.~ * receiving intermittent renal replacement therapy (RRT).~ * Failure of enteral feeding or any contraindication to enteral administration.~ * Obesity , body mass index (BMI \> 35 kg/m2)~ * Known contraindication to vitamin C or thiamine (oxalate nephropathy or known glucose-6-phosphate dehydrogenase deficiency)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low risk group (Type: NO_INTERVENTION): no specific treatment will be given
- High risk control (Type: NO_INTERVENTION): no specific treatment will be given
- High risk DP (Type: ACTIVE_COMPARATOR): patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
- High risk CB (Type: ACTIVE_COMPARATOR): Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).